Vanguard Personalized Indexing Management LLC Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Vanguard Personalized Indexing Management LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,374 shares of the company’s stock, valued at approximately $252,000.

A number of other large investors also recently added to or reduced their stakes in KRYS. Scout Investments Inc. bought a new stake in shares of Krystal Biotech in the 1st quarter valued at about $8,976,000. Sei Investments Co. grew its holdings in shares of Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after purchasing an additional 18,968 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after buying an additional 35,632 shares during the period. Janney Montgomery Scott LLC bought a new stake in Krystal Biotech during the 1st quarter valued at $3,175,000. Finally, Braidwell LP boosted its position in Krystal Biotech by 153.2% during the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock valued at $24,341,000 after buying an additional 118,703 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $177.14 on Monday. The company has a 50 day simple moving average of $192.47 and a two-hundred day simple moving average of $179.64. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The company has a market capitalization of $5.06 billion, a price-to-earnings ratio of 94.73 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. During the same quarter in the previous year, the business earned ($1.25) earnings per share. The firm’s quarterly revenue was up 70283900.0% compared to the same quarter last year. On average, analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KRYS. Citigroup reissued a “neutral” rating and issued a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. HC Wainwright raised their price target on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).